Jiangsu Safe Pharmaceutical Co., Ltd (hereinafter named ˇ°SAFEˇ±) is located in the Wuxi National Hi-tech Development Zone. SAFE is established on the foundation of capital-reconstructed of the bankrupted Wuxi ICN Pharmaceutical Co., Ltd., in July 2004, SAFE Passed by the GMP authentication of State Drug administration.
SAFE covers an area of 88.8 mu in Wuxi National Hi-tech Development Zone, which already build an area of 1200 m 2 and reserved an area of 45 mu for development in future. Surrounded with trees and flowers, the environment of SAFE is quiet and beautiful. It takes some famous corporation as its neighbors, such as LG, Simens etc. The company has a convenient traffic, which is near by national road G312 and very close to the entrance of expressway and Shuofang Airport.
As a project of investment-attraction by government, the company is well-received good service from New District Government and attracted more attention and support of SFDA as a new re-combined enterprise.
SAFE currently has four product lines of soft capsules (reserved another 2 lines) and one line each for manufacturing capsules, tablets, creams and suppositories. The excellent utilities and advanced equipments enable it to meet the requirements of quality control and R & D. It also has complete facilities of living, environment-protection, fire protection and telecommunication etc.
SAFE has a reasonable organization structure and a team of skillful employees. It currently meets the requirements of enterprise management, marketing and technology updating.
SAFE has 30 products at present, Among them, Jindeming? capsules (Ciclosporin soft capsules), Squalene soft capsules. Both of them are high profits and have great potential demand of market. Besides, SAFE has 3 items from raw material to finished products.
At present, SAFE takes Jiangsu, Shanghai and Beijing etc. as its major target markets and develops other markets as well. It also begins to extent the clinic network.
SAFE has settled its development orientation as follows: First, being specialized and continuous in the field of apparatus transplant, apply for two National Class-II new medicines in the next 2 or 3 years based on the extended network and brand effect of Ciclosporin soft capsules. Secondly, develop one or two National Class- ˘ô medicines to complete its product structure.
ˇ°Dedicated for caring allˇ± is enterprise ideal of SAFE. We will unceasingly improve ourselves to supply the best products and service to our customers.
